BC Cancer scientist Dr. Ly Vu is one of 11 recipients of A Grant of Her Own: The Women Scientists Innovation Award for Cancer Research. This new granting program, developed by the V Foundation for Cancer Research, sees $8 million in funding invested in cancer research being led by women scientists. Dr.
Dr. Joseph Lau is working to develop the next generation of radiopharmaceuticals for both diagnostic and therapeutic purposes. Radiopharmaceuticals are radioactive compounds used in cancer care. From a diagnostic perspective, his work focusses on making these radioactive agents better able to detect and visualize cancers in the body. From a treatment perspective this helps oncologists determine if a cancer is operable, delineates margins for radiation planning or select targeted-therapies based on molecular properties of cancer.
Dr. Carol Chen is dedicated to understanding the complexities and finding innovative solutions to high-grade gliomas (HGGs); a particularly aggressive form of brain cancer affecting children and young adults. The new BC Cancer scientist, who joined the Terry Fox Laboratory in 2023, is focused on understanding how mutations in certain proteins, called histones or histone-modifying enzymes, contribute to the development of HGGs.
ARCC is pleased to announce that its 12th annual conference, ARCC2023, will take place virtually on September 14-15, 2023. The objective of this conference is to bridge a connection between researchers and decision-makers, using health economics, services, policy and ethics research to improve cancer control and the delivery of cancer care.
Congratulations to Dr. Renelle Myers (Myers Lab) and team for being awarded a CCS Team Breakthrough Grant: Transforming Low-Survival Cancers for the project titled "Improving Detection of Early Lung Cancer in a Diverse Population (IDEAL) study". Dr. Myers was awarded $5.4 million over 5 years.
Researchers at the BC Cancer Research Institute have made an advancement in genetic testing that allows for more accurate prediction of which parent’s genes led to an individual’s increased cancer risk. This improves the efficiency of familial testing strategies and could eliminate concern for patients at high risk of cancer caused by genes inherited from a parent.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.